Am Fam Physician. 2025;112(1):22-23
Author disclosure: No relevant financial relationships.
| Drug | Dosage | Dose form | Cost of full course* |
|---|---|---|---|
| Benzgalantamine (Zunveyl) | 5 mg twice daily; increase as needed to 10 mg twice daily after 4 weeks, to a maximum dosage of 15 mg twice daily | 5-mg, 10-mg, and 15-mg delayed-release tablets | Approximately $800 |
Benzgalantamine (Zunveyl) is labeled for the treatment of mild to moderate Alzheimer disease in adults. It is metabolized to galantamine, which is a competitive and reversible cholinesterase inhibitor. Benzgalantamine is thought to prevent degradation of acetylcholine and enhance cholinergic function.1 There are no published clinical trials of benzgalantamine. It was approved for marketing based on evidence from bioavailability studies comparing it with galantamine immediate-release tablets and extended-release capsules.
Already a member/subscriber?
Log In
Subscribe
From $180- Immediate, unlimited access to all AFP content
- More than 125 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Interested in AAFP membership?
Learn More
